NAD+ Skincare in 2026: The Cellular Energy Revolution Reshaping Anti-Aging Science

Industry Insights · September 11, 2026

The Cellular Energy Crisis Hitting Your Skin

By the time you reach 40, your skin cells have lost roughly 40–50% of the NAD+ they had in your twenties. This isn’t a gradual, gentle decline — it’s an accelerating freefall driven by increased CD38 enzyme activity, chronic UV exposure, and oxidative stress. NAD+ (nicotinamide adenine dinucleotide) is the coenzyme that powers mitochondrial ATP production, activates sirtuin longevity proteins, and fuels PARP-mediated DNA repair. Without sufficient NAD+, skin fibroblasts slow collagen synthesis, keratinocytes weaken barrier lipid production, and melanocytes become dysregulated — the trifecta of visible aging.

Unlike previous “hero ingredient” trends built on marketing velocity, NAD+ arrives in skincare with a Nobel-adjacent scientific foundation. The sirtuin-NAD+ axis earned the 2009 Nobel Prize in Medicine. Over 12,000 peer-reviewed publications reference NAD+ in cellular biology. The question for the skincare industry in 2026 isn’t whether NAD+ matters for skin — it’s whether topical formulations can actually deliver it where it counts.

Market Momentum: From Biohacking to Beauty Counter

The global NAD+ market reached $6.48 billion in 2026, growing at a CAGR of 16.1%, according to The Business Research Company. Within this, the skincare-specific NAD+ segment is expanding even faster — Mintel reports that while NAD+-claiming skincare launches represent less than 1% of global beauty new product development, the category has grown over 10× in five years. The bulk of these launches emerged from the US, China, South Korea, and the UK.

South Korea is leading formulation innovation. LG Household & Health Care invested over a decade in NAD+ skin delivery research, culminating in the NAD Power 24™ liposomal delivery system used across THE WHOO’s premium lines. The Korean MFDS has begun preliminary reviews of NAD+-related cosmetic ingredient registrations, signaling regulatory engagement that could set precedents for ASEAN and EU frameworks.

On the consumer side, 37% of Chinese women surveyed by Mintel expressed willingness to pay premium prices for NMN-containing skincare — a data point that hasn’t escaped Southeast Asian brand strategists targeting the same demographic psychographic.

The Penetration Problem — and Who’s Solving It

Here’s the technical reality that separates serious NAD+ formulations from marketing theater: NAD+ is a 663-dalton, highly polar, water-soluble molecule. The stratum corneum — skin’s lipid-rich outer barrier — is designed to keep exactly this type of molecule out. Applied topically without a delivery system, NAD+ sits on the surface and degrades.

This is why the meaningful innovation isn’t in the ingredient itself but in the delivery vehicle. Three approaches currently dominate:

• Liposomal encapsulation: Wrapping NAD+ in phospholipid bilayers enables fusion with stratum corneum lipids, dramatically improving penetration. A 2024 in vitro study in PMC demonstrated that liposomal NAD+ formulations had significantly stronger effects on cellular senescence markers in keratinocytes than free NAD+ solutions. THE WHOO’s NAD Power 24™ uses this approach with a decade of stability data.
• Precursor strategies: Niacinamide (vitamin B3) is the most clinically validated NAD+ precursor for topical use. A myristyl nicotinate cream increased skin NAD+ by 25%, improved epidermal thickness by 20%, and reduced transepidermal water loss by 20% in controlled studies (Jacobson et al., Journal of Cosmetic Dermatology). NMN (nicotinamide mononucleotide) — one metabolic step closer to NAD+ — has shown dermal penetration in skin-mimetic membrane models and is gaining traction in Korean formulations.
• CD38 inhibitor stacking: A 2024 study showed that combining exogenous NAD+ with CD38 inhibitors (quercetin and enoxolone) achieved 55.82% inhibition of the enzyme that destroys NAD+ in skin cells. This “protect and supply” strategy effectively extends the functional half-life of topically delivered NAD+.

What the Clinical Evidence Actually Shows

The evidence landscape for topical NAD+ in 2026 is best described as mechanistically strong, clinically emerging. Here’s what the data supports — and what it doesn’t.

Established: Niacinamide as NAD+ Booster

Multiple randomized controlled trials at 2–5% niacinamide concentrations demonstrate statistically significant improvements in fine lines, elasticity, barrier function, and hyperpigmentation. Niacinamide reliably raises intracellular NAD+ in skin cells, fueling sirtuin activation and DNA repair pathways. This is the gold-standard NAD+ skincare ingredient today — not because it’s the most direct, but because it’s small, stable, penetrates effectively, and has decades of clinical backing.

Promising: Direct NAD+ and NMN Topical

A clinical trial of 1% NAD+ ointment in 37 psoriasis patients showed efficacy comparable to 0.1% anthralin in reducing erythema, infiltration, and desquamation — with fewer side effects and better cosmetic acceptability (Wozniacka et al., Acta Dermato-Venereologica). However, the formulation required refrigeration for stability, highlighting a real-world formulation challenge.

For NMN, a 2022 study found that NMN reduced melanin production in aged melanocytes by downregulating melanogenesis-related signaling — suggesting potential for hyperpigmentation applications. Mouse models show oral NMN reduces wrinkle depth, improves hydration, and restores barrier function after UV-B exposure. Human topical trials remain scarce but are underway.

Not Yet Established: Anti-Aging Structural Claims

No published randomized controlled trial demonstrates that topical NAD+ or NMN alone reduces deep wrinkles or increases dermal collagen density in healthy human skin. The 2025 consensus statement from the Association of Cutaneous Surgeons of India rated the available NAD+ evidence at the lowest level, noting most data is extrapolated from molecular biology rather than dermatology-specific clinical trials. Any product claiming “clinically proven wrinkle reduction” from NAD+ specifically — as opposed to from niacinamide — is overstating the evidence.

The Strategic Landscape for Brands

For formulators and brand strategists, the NAD+ opportunity in 2026 has three distinct entry points:

1. Niacinamide-forward positioning: Leverage the established NAD+ pathway without making NAD+ the hero claim. This is the lowest-risk, highest-evidence strategy. Products at 4–5% niacinamide with supportive barrier lipids can credibly claim “cellular energy support” and “DNA repair optimization” within cosmetic claim frameworks.
2. NMN as differentiated active: With only 14% of NAD+-claiming skincare launches currently using NMN, there’s a clear innovation gap. NMN’s one-step conversion to NAD+ offers a more direct mechanism story than niacinamide, and early melanogenesis data supports a hyperpigmentation-angle positioning. Brands need encapsulation technology to justify the premium pricing that 37% of Chinese consumers will pay.
3. Liposomal NAD+ with CD38 inhibitors: The most scientifically ambitious approach — direct NAD+ delivery with quercetin or enoxolone to prevent enzymatic degradation. This requires significant formulation investment and stability testing, but it’s the strategy most likely to generate proprietary clinical data and patent protection.

Regulatory Outlook: What’s Coming

The regulatory landscape for NAD+ in cosmetics is still forming. In the EU, NAD+ falls under standard cosmetic ingredient regulations (EC No 1223/2009), with no specific restrictions on niacinamide or NMN in topical formulations. The US FDA has not issued cosmetic-specific guidance on NAD+ — though its 2019 consumer alert on injectable exosome products created caution that extends to any regenerative medicine-adjacent ingredient. Korea’s MFDS is the most active regulator in this space, with preliminary reviews of NAD+-related functional cosmetic ingredient registrations underway in 2026.

For Southeast Asian markets under the ASEAN Cosmetic Directive, NAD+ and its precursors are not restricted ingredients. However, claims must stay within cosmetic boundaries — “supports cellular energy,” “helps maintain skin vitality,” and “reinforces barrier function” are defensible. “Treats aging,” “repairs DNA damage,” and “reverses cellular senescence” are not.

The Bottom Line

NAD+ skincare in 2026 occupies the same inflection point that retinol did in the early 2000s or peptides did in the 2010s: strong mechanistic science, growing consumer awareness, emerging clinical data, and significant formulation challenges that create barriers to entry. The brands that will win are those that invest in delivery technology rather than ingredient marketing, that position NAD+ alongside established actives rather than as a replacement, and that generate proprietary clinical data rather than borrowing from oral supplementation research.

For consumers and practitioners, the practical guidance is straightforward: niacinamide remains the most evidence-backed way to support skin NAD+ topically. NMN and direct NAD+ formulations with liposomal delivery are the space to watch — but validate the delivery system before validating the ingredient.

References

1. Camacho-Pereira A, et al. CD38 Dictates Age-Related NAD+ Decline and Mitochondrial Dysfunction. Cell Metabolism. 2016;24(2):244-255.
2. Wozniacka A, et al. Topical application of NAD+ for psoriasis treatment. Acta Dermato-Venereologica. 2007;87(3):253-254.
3. Jacobson EL, et al. A topical lipophilic niacin derivative increases skin NAD content. Journal of Cosmetic Dermatology. 2007;6(4):244-249.
4. Park J, et al. Exogenous NAD+ combined with CD38 inhibitors enhances fibroblast function. PMC/International Journal of Molecular Sciences. 2024;25(8):4291.
5. Mintel. 2026 Global Beauty & Personal Care Ingredients Trend Report. Mintel Group Ltd., 2026.
6. The Business Research Company. Nicotinamide Adenine Dinucleotide Global Market Report 2026. February 2026.
7. Association of Cutaneous Surgeons of India. Consensus Statement on NAD+ in Dermatology. 2025.
8. Kim H, et al. Systematic review of MSC-derived exosomes for skin regeneration. International Journal of Molecular Sciences. 2025;26(3):1567.